最新临床试验:抗雄激素和放疗是否联用多西紫杉醇治疗手术切除后的前列腺癌

USNEWS:避免吃致癌的食物与健康饮食!
2019年10月12日
USNEWS:所有人都适合做DNA测试吗?
2019年10月17日
显示所有

这是经美国国家癌症研究所批准的一项多中心随机对照II / III期临床试验,目的是研究多西紫杉醇、抗雄激素和放射治疗,与单纯抗雄激素和放射治疗相比,在治疗通过手术切除后的前列腺癌患者方面的效果。雄激素能引起前列腺细胞的生长,抗激素治疗可以减少体内产生的雄激素。放射治疗使用高能x射线杀死肿瘤细胞和缩小肿瘤。用于化疗的药物,如多西紫杉醇,以不同的方式阻止肿瘤细胞的生长,包括通过杀死细胞,阻止细胞分裂,或阻止它们扩散。术后给予抗雄激素和放疗加或不加多西紫杉醇可能杀死更多残留的肿瘤细胞。

该临床试验正在全美237家医院进行开展。

This randomized phase II / III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery. Androgen can cause the growth of prostate cells. Antihormone therapy may lessen the amount of androgen made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving antiandrogen therapy and radiation therapy with or without docetaxel after surgery may kill any remaining tumor cells.

Lead Organization

Lead Organization
NRG Oncology

Principal Investigator
Mark David Hurwitz

Trial IDs

Primary ID NRG-GU002
Secondary IDs NCI-2016-00963
Clinicaltrials.gov ID NCT03070886
Status: Active
Age: 18 years and over
Gender: Male
Location: 237 locations

发表评论